Hållbar UPPHANDLING
Ett samarbete mellan Sveriges regioner

Summary of Re-audit Follow-Up Results

Below is a summary of a follow-up on sustainability requirements for a supplier to Sweden's regions. The summary reflects the results of the audit as well as activities carried out as a result. It has been updated continuously as new activities related to the follow-up have been conducted, until all potential non-conformities have been addressed and the follow-up is considered complete.
For questions regarding the summary, please contact the Regional Office for Sustainable Procurement.

www.husr.se

Log

Last updated	2025-06-18

General Information

Supplier	Baxter Medical AB
Regions with Agreement	Västra Götalandsregionen
Risk Area	Pharmaceuticals/Läkemedel
Product	Cytostatic drug
Type of Follow-Up	Desk review
Requirement	Sustainable supply chain
Re-audit Date	2025-05-06
For more information	For more information or for the report please contact Jenny Forsell Skoog, jenny.forsell.skoog@vgregion.se

Re-audit Results

Summary of the Re-audit	Baxter Medical AB has systems in order to communicate its contractual terms and collects documentation to follow up with its suppliers via Ecovadis. However, they have not yet fully demonstrated a sufficiently developed and systematic approach to risk analysis that relates to these activities, including the origin of raw materials, and have not identified or prioritized risks in their supply chain related to the sample product. Additionally, . Additionally, Baxter Medical AB has not yet fully demonstrated a sufficiently structured approach to deviation management process that encompasses the supply chain, and the deficiencies in risk analysis, follow-up, and deviation handling remain for the sampled product.

Audit Results	**Sustainable Supply Chains**	**Assessment***
	1. Policy Commitment	
	2. Forwarding of commitment	
	3. Allocation of Responsibilities	
	4. Risk Assessment	
	5. Follow-Up	
	6. Non-Conformance Management	

Explanations	
Non-Conformance	
No identified non-conformities	

*For a detailed description, see Appendix 1. Non-Conformities

Next Actions	Action plan, re-audit recommended

Appendix 1 - Non-Conformities

	Sustainable Supply Chains
Non-Conformity	Baxter has not yet presented a systematic approach to risk analysis or identified risks for the sample product.
Supplier's Action	Baxter will formalize a supplier risk analysis process to assess human rights risks within the supply chain using internal and external resources and other available data. - This will involve identification of high-risk countries. - This process will be described and controlled by a procedure.
Timeline	31 Dec 2025
Non-Conformity	Baxter has not yet fully described activities undertaken to systematically follow up on compliance with the contract terms within their own operations or in the supply chain for the sample product.
Supplier's Action	Baxter's supplier risk management process will define the process to identify and monitor compliance with contractual terms. This supplier risk management process will be described by the procedure referenced in observation 1
Timeline	31 Dec 2025
Non-Conformity	Baxter has not yet fully demonstrated whether any deviations from contract terms have occurred during the contract period in relation to the goods or services covered by the agreement. Baxter has also not yet fully described a systematic deviation management process within their own operations or in the supply chain for the sample product when considering the severity of the deviation.
Supplier's Action	Baxter's supplier risk management process will describe the deviation process including the severity of the deviation. The process will define the appropriate escalation or enforcement action. This process will be described by the procedure referenced in observation 1.
Timeline	31 Dec 2025